CIK 0001737953 · Non-accelerated filer<br>Smaller reporting company
Replimune Group, Inc.
Sign in to watch- Ticker
- REPL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 822082553
- Phone
- (781) 222-9600
- Business address
- 500 UNICORN PARK, WOBURN, MA, 01801
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $654,036
- in 3 filings
Net −$654,036. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-18 | Xynos Konstantinos Chief Medical Officer | Sale | −7,246 | $10.78 | $78K | 109,885 |
| 2024-11-18 | Sarchi Christopher Chief Commercial Officer | Sale | −5,207 | $10.78 | $56K | 87,045 |
| 2024-09-04 | Balachandran Madhavan Director | Grant or award · Employee Stock Option (right to buy) | +64,000 | 64,000 | ||
| 2024-08-30 | Astley-Sparke Philip Executive Chairman | Gift | −50,000 | 1,437,350 | ||
| 2024-08-16 | Hill Emily Luisa Chief Financial Officer | Sale | −8,938 | $10.18 | $91K | 101,057 |
| 2024-06-07 | Xynos Konstantinos Chief Medical Officer | Sale 10b5-1 | −15,881 | $7.50 | $119K | 117,131 |
| 2024-05-16 | Sarchi Christopher Chief Commercial Officer | Sale | −2,218 | $6.47 | $14K | 92,252 |
| 2024-05-16 | Schwendenman Andrew Chief Accounting Officer | Sale | −2,298 | $6.47 | $15K | 38,238 |
| 2024-05-16 | Love Colin Chief Operating Officer | Sale | −17,615 | $6.47 | $114K | 777,345 |
| 2024-05-16 | Astley-Sparke Philip Executive Chairman | Sale | −37,928 | $6.47 | $245K | 1,487,350 |
| 2024-05-16 | Coffin Robert Director | Sale | −11,464 | $6.47 | $74K | 1,821,872 |
| 2024-05-16 | Patel Sushil Chief Executive Officer | Sale | −20,194 | $6.47 | $131K | 212,014 |
| 2024-05-16 | Xynos Konstantinos Chief Medical Officer | Sale | −6,367 | $6.47 | $41K | 133,012 |
| 2024-04-01 | Peeples-Dyer Veleka Director | Grant or award · Stock Option (right to buy) | +32,000 | 32,000 | ||
| 2024-04-01 | Patel Sushil Chief Executive Officer | Grant or award | +83,335 | 232,208 | ||
| 2024-04-01 | Patel Sushil Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2024-04-01 | Pucci Paolo Director | Grant or award · Stock Option (right to buy) | +32,000 | 32,000 | ||
| 2024-04-01 | Xynos Konstantinos Chief Medical Officer | Grant or award | +26,665 | 139,379 | ||
| 2024-04-01 | Xynos Konstantinos Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +80,000 | 80,000 | ||
| 2024-04-01 | Dhingra Kapil Director | Grant or award · Stock Option (right to buy) | +32,000 | 32,000 |
Page 5 of 8 · 143 trades